• Something wrong with this record ?

Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience

J. Radocha, P. Paterová, A. Zavřelová, B. Víšek, F. Gabalec, H. Žemličková, P. Žák,

. 2018 ; 63 (2) : 141-146. [pub] 20170803

Language English Country United States

Document type Journal Article

Grant support
NV17-28539A MZ0 CEP Register

Viridans group streptococci bloodstream infections (VGS BSI) remain a significant cause of mortality and morbidity in patients with severe neutropenia. The goal of our study was to evaluate clinical course and microbiological susceptibility of VGS BSI at our center. Retrospective analysis of all microbiologically documented bloodstream infections caused by VGS during the 9-year time period (from January 2006 until December 2014) was carried out. Only patients with severe neutropenia (< 500/μL) were included in the study. Clinical outcome and microbiological susceptibility pattern of isolates were recorded. Fifty-one individual patients with episode of VGS BSI were identified. The most frequent agent was Streptococcus mitis (23/51 cases, 45.1%). 88.2% (45/51) of patients were on recommended ciprofloxacin prophylaxis. 20/51 (39.2%) of patients suffered from mucositis at the time of diagnosis (10 patients had oral mucositis, 2 patients had bowel mucositis, and 8 patients both). Twenty-six patients (51.0%) had clinically relevant lung damage caused by VGS BSI (i.e., acute lung injury or acute respiratory distress syndrome). Twenty-four (47.0%) patients presented with bilateral lung infiltrated upon chest imaging, and two (4.0%) patients had unilateral lung infiltrates. Three patients (5.9%) died due to VGS BSI until day 28 of observation. No difference in signs of shock syndrome was observed in the patients during transplantation procedures compared to patients without transplantation as well as in a group received previous high-dose chemotherapy with cytosinarabinoside or in patients with mucositis. Only 3/51 of isolates (5.9%) were resistant to penicillin. All isolates were susceptible to empirical treatment. While the penicillin resistance of VGS remains low in middle Europe, initial antibiotic therapy of febrile neutropenia are still effective in most cases. The mortality and complication rates of VGS BSI were comparable to other studies, and no specific risk factor of shock presence could be identified.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18028582
003      
CZ-PrNML
005      
20190304084101.0
007      
ta
008      
180816s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12223-017-0542-7 $2 doi
035    __
$a (PubMed)28776170
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Radocha, Jakub $7 xx0233189 $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic. jakub.radocha@centrum.cz.
245    10
$a Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience / $c J. Radocha, P. Paterová, A. Zavřelová, B. Víšek, F. Gabalec, H. Žemličková, P. Žák,
520    9_
$a Viridans group streptococci bloodstream infections (VGS BSI) remain a significant cause of mortality and morbidity in patients with severe neutropenia. The goal of our study was to evaluate clinical course and microbiological susceptibility of VGS BSI at our center. Retrospective analysis of all microbiologically documented bloodstream infections caused by VGS during the 9-year time period (from January 2006 until December 2014) was carried out. Only patients with severe neutropenia (< 500/μL) were included in the study. Clinical outcome and microbiological susceptibility pattern of isolates were recorded. Fifty-one individual patients with episode of VGS BSI were identified. The most frequent agent was Streptococcus mitis (23/51 cases, 45.1%). 88.2% (45/51) of patients were on recommended ciprofloxacin prophylaxis. 20/51 (39.2%) of patients suffered from mucositis at the time of diagnosis (10 patients had oral mucositis, 2 patients had bowel mucositis, and 8 patients both). Twenty-six patients (51.0%) had clinically relevant lung damage caused by VGS BSI (i.e., acute lung injury or acute respiratory distress syndrome). Twenty-four (47.0%) patients presented with bilateral lung infiltrated upon chest imaging, and two (4.0%) patients had unilateral lung infiltrates. Three patients (5.9%) died due to VGS BSI until day 28 of observation. No difference in signs of shock syndrome was observed in the patients during transplantation procedures compared to patients without transplantation as well as in a group received previous high-dose chemotherapy with cytosinarabinoside or in patients with mucositis. Only 3/51 of isolates (5.9%) were resistant to penicillin. All isolates were susceptible to empirical treatment. While the penicillin resistance of VGS remains low in middle Europe, initial antibiotic therapy of febrile neutropenia are still effective in most cases. The mortality and complication rates of VGS BSI were comparable to other studies, and no specific risk factor of shock presence could be identified.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antibakteriální látky $x aplikace a dávkování $7 D000900
650    _2
$a bakteriemie $x farmakoterapie $x mikrobiologie $7 D016470
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hematologické nádory $x farmakoterapie $x mikrobiologie $7 D019337
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a streptokokové infekce $x farmakoterapie $x mikrobiologie $7 D013290
650    _2
$a viridující streptokoky $x klasifikace $x účinky léků $x genetika $x izolace a purifikace $7 D034363
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Paterová, P $u Institute of Clinical Microbiology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Zavřelová, A $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Víšek, B $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Gabalec, F $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Žemličková, H $u Institute of Clinical Microbiology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
700    1_
$a Žák, P $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
773    0_
$w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 63, č. 2 (2018), s. 141-146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28776170 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180816 $b ABA008
991    __
$a 20190304084412 $b ABA008
999    __
$a ok $b bmc $g 1326576 $s 1025537
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 63 $c 2 $d 141-146 $e 20170803 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
GRA    __
$a NV17-28539A $p MZ0
LZP    __
$a Pubmed-20180816

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...